FXN and Friedreich ataxia: Two preclinical studies, performed on cardiac and sensory mouse models of FRDA using adeno-associated virus (AAV) vectors to express frataxin, showed that intravenous injection of an AAV vector expressing FXN not only prevented the development of cardiac and neurological features, but also improved cellular functions when injections were made in symptomatic mice [35,36].